The field of biosimilar contenders for anti–vascular endothelial growth factor (anti-VEGF) therapies is taking shape, with biosimilar developer Coherus seeking to launch its ranibizumab biosimilar in 2021 and Samsung Bioepis having reached a commercialization agreement for 2 biosimilar anti-VEGFs of its own. Last week, a study published in JAMA Ophthalmology supported the use of anti-VEGF agents in wet age-related macular degeneration (AMD), saying that, though these drugs are costly, they may provide substantial economic value to both patients and society.
The field of biosimilar contenders for anti—vascular endothelial growth factor (anti-VEGF) therapies is taking shape, with biosimilar developer Coherus seeking to launch its ranibizumab biosimilar in 2021 and Samsung Bioepis having reached a commercialization agreement for 2 biosimilar anti-VEGFs of its own. Last week, a study published in JAMA Ophthalmology supported the use of anti-VEGF agents in wet age-related macular degeneration (AMD), saying that, though these drugs are costly, they may provide substantial economic value to both patients and society.1
The economic evaluation study used data from the published literature to simulate vision outcomes for a cohort of 168,820 patients with wet AMD. The researchers assumed the cohort was aged 65 years or older, and that baseline visual acuity (VA) was 55 letters. They considered 2 treatment scenarios: one in which patients receive approximately 8.2 (standard deviation [SD] 1.6) injections each year, and one in which patients receive approximately 10.5 (range, 6.8-13.1) injections each year (the second scenario reflects dosing for ranibizumab).
VA was translated into quality-adjusted life-years (QALYs) at a conversion rate of $150,000 per QALY gained.
From an individual patient standpoint, the VA improvements in the first scenario translated into $10,918 in economic benefits at 1 year, $32,158 at 3 years, and $49,558 at 5 years. The second scenario generated $15,525, $50,839, and $84,873 in benefits at the same 3 time points.
For the full cohort, the first scenario generated $1.1 billion in patient benefits in year 1, and the second scenario generated $1.6 billion. At 3 years, patient benefits from the first scenario increased to $5.1 billion, and patient benefits from the second scenario increased to $8.2 billion. Societal value, measured as patient benefits net of treatment cost, ranged from $0.9 billion to $3.0 billion across 3 years.
Additionally, the authors note that using bevacizumab off-label, instead of using aflibercept or ranibizumab, in 72% of the market (up from a current 55% of the market) could bring down total costs to treat the full population by $1.8 billion to $2.2 billion over 3 years.
If patient outcomes match the data used in these analyses, say the authors, improved vision associated with anti-VEGF treatment could provide substantial value to patients and society. Innovations that improve adherence, such as improved drug delivery, could provide even more value.
In a linked commentary, Melissa M. Brown, MD, MN, MBA, and Gary C. Brown, MD, MBA, write that they find the $150,000 per QALY measure to be “somewhat arbitrary,” however, and suggested that different anti-VEGF therapy percentage weights could have been used in the analysis.2 “Nonetheless,” they write, “the results likely still would have shown that patients and society retain substantial dollars with VEGF inhibitor therapy.” They add that, while most cost-utility analyses do not consider societal costs, “We agree with the authors that their type of analyses are key for ophthalmology, especially if the competition for health care dollars intensifies.”
References
1. Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic value of anti—vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States [published online November 14, 2019]. JAMA Ophthalmol. doi: 10.1001/jamaophthalmol.2019.4557.
2. Brown MM, Brown GC. Economic evaluation of anti—vascular endothelial growth factor therapy for wet age-related macular degeneration [published online November 14, 2019]. JAMA Ophtalmol. doi:10.1001/jamaophthalmol.2019.4582.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.